# REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

> **NCT04523428** · PHASE2 · RECRUITING · sponsor: **Stichting Hemato-Oncologie voor Volwassenen Nederland** · enrollment: 60 (estimated)

## Conditions studied

- CLL/SLL

## Interventions

- **DRUG:** Venetoclax/Acalabrutinib

## Key facts

- **NCT ID:** NCT04523428
- **Lead sponsor:** Stichting Hemato-Oncologie voor Volwassenen Nederland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-23
- **Primary completion:** 2028-12
- **Final completion:** 2032-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04523428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04523428, "REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04523428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*